Stress-related depression: Neuroendocrine, genetic, and therapeutical aspects

References

• Anacker C, Zunszain PA, Cattaneo A, Carvalho LA, Garabedian MJ, Thuret S, . 2011. Antidepressants increase human hippocampal neurogenesis by activating the glucocorticoid receptor. Mol Psychiatry 16(7):738–50.
   PubMedGoogle Scholar
• Anguelova M, Benkelfat C, Turecki G. 2003. A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter: I. Affective disorders. Mol Psychiatry 8(6):574–591.
   PubMedGoogle Scholar
• Appel K, Schwahn C, Mahler J, Schulz A, Spitzer C, Fenske K, . 2011. Moderation of adult depression by a polymorphism in the FKBP5 gene and childhood physical abuse in the general population. Neuropsychopharmacology 36(10): 1982–1991.
   PubMedGoogle Scholar
• Bachmann CG, Linthorst AC, Holsboer F, Reul JM. 2003. Effect of chronic administration of selective glucocorticoid receptor antagonists on the rat hypothalamic-pituitary-adrenocortical axis. Neuropsychopharmacology 28(6):1056–1067.
   PubMedGoogle Scholar
• Baghai TC, Binder EB, Schule C, Salyakina D, Eser D, Lucae S, . 2006. Polymorphisms in the angiotensin-converting enzyme gene are associated with unipolar depression, ACE activity and hypercortisolism. Mol Psychiatry 11(11): 1003–1015.
   PubMedGoogle Scholar
• Barbaccia ML. 2004. Neurosteroidogenesis: relevance to neurosteroid actions in brain and modulation by psychotropic drugs. Crit Rev Neurobiol 16(1–2):67–74.
   PubMedGoogle Scholar
• Behan DP, Potter E, Lewis KA, Jenkins NA, Copeland N, Lowry PJ, Vale WW. 1993. Cloning and structure of the human corticotrophin releasing factor-binding protein gene (CRHBP). Genomics 16(1):63–68.
   PubMedGoogle Scholar
• Binder EB. 2009. The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. Psychoneuroendocrinology 34(Suppl 1):S186–195.
   PubMed Web of Science ®Google Scholar
• Binder EB, Holsboer F. 2006. Pharmacogenomics and antidepressant drugs. Ann Med 38(2):82–94.
   PubMedGoogle Scholar
• Binder EB, Nemeroff CB. 2010. The CRF system, stress, depression and anxiety-insights from human genetic studies. Mol Psychiatry 15(6):574–588.
   PubMedGoogle Scholar
• Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M, Putz B, . 2004. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 36(12): 1319–1325.
   PubMedGoogle Scholar
• Binder EB, Kunzel HE, Nickel T, Kern N, Pfennig A, Majer M, . 2009. HPA-axis regulation at in-patient admission is associated with antidepressant therapy outcome in male but not in female depressed patients. Psychoneuroendocrinology 34(1):99–109.
   PubMedGoogle Scholar
• Binder EB, Owens MJ, Liu W, Deveau TC, Rush AJ, Trivedi MH, . 2010. Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response. Arch Gen Psychiatry 67(4):369–379.
   PubMedGoogle Scholar
• Binneman B, Feltner D, Kolluri S, Shi Y, Qiu R, Stiger T. 2008. A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am J Psychiatry 165(5):617–620.
   PubMedGoogle Scholar
• Boorse GC, Denver RJ. 2006. Widespread tissue distribution and diverse functions of corticotropin-releasing factor and related peptides. Gen Comp Endocrinol 146(1):9–18.
   PubMedGoogle Scholar
• Bosch OG, Quednow BB, Seifritz E, Wetter TC. 2011. Reconsidering GHB: orphan drug or new model antidepressant? J Psychopharmacol 108(16):6621–5.
   Google Scholar
• Bosker FJ, Hartman CA, Nolte IM, Prins BP, Terpstra P, Posthuma D, . 2011. Poor replication of candidate genes for major depressive disorder using genome-wide association data. Mol Psychiatry 16(5):516–532.
   PubMed Web of Science ®Google Scholar
• Bradley RG, Binder EB, Epstein MP, Tang Y, Nair HP, Liu W, . 2008. Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene. Arch Gen Psychiatry 65(2):190–200.
   PubMedGoogle Scholar
• Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, . 2003. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301(5631): 386–389.
   PubMed Web of Science ®Google Scholar
• Chowdrey HS, Larsen PJ, Harbuz MS, Jessop DS, Aguilera G, Eckland DJ, Lightman SL. 1995. Evidence for arginine vasopressin as the primary activator of the HPA axis during adjuvant-induced arthritis. Br J Pharmacol 116(5):2417–2424.
   PubMedGoogle Scholar
• Claes S. 2009. Glucocorticoid receptor polymorphisms in major depression. Ann NY Acad Sci 1179:216–228.
   PubMed Web of Science ®Google Scholar
• Clarke H, Flint J, Attwood AS, Munafo MR. 2010. Association of the 5-HTTLPR genotype and unipolar depression: a meta-analysis. Psychol Med 40(11):1767–1778.
   PubMed Web of Science ®Google Scholar
• Cyranowski JM, Hofkens TL, Frank E, Seltman H, Cai HM, Amico JA. 2008. Evidence of dysregulated peripheral oxytocin release among depressed women. Psychosom Med 70(9): 967–975.
   PubMedGoogle Scholar
• de Kloet ER, Derijk RH, Meijer OC. 2007. Therapy Insight: is there an imbalanced response of mineralocorticoid and glucocorticoid receptors in depression? Nat Clin Pract Endocrinol Metab 3(2):168–179.
   PubMedGoogle Scholar
• de Quervain DJ, Bentz D, Michael T, Bolt OC, Wiederhold BK, Margraf J, Wilhelm FH. 2011. Glucocorticoids enhance extinction-based psychotherapy. Proc Natl Acad Sci USA 108(16): 6621–5.
   PubMed Web of Science ®Google Scholar
• DeRijk RH, de Kloet ER. 2008. Corticosteroid receptor poly morphisms: determinants of vulnerability and resilience. Eur J Pharmacol 583(2–3):303–311.
   PubMedGoogle Scholar
• DeRijk RH, de Kloet ER, Zitman FG, van Leeuwen N. 2011. Mineralocorticoid receptor gene variants as determinants of HPA axis regulation and behavior. Endocr Dev 20:137–148.
   PubMedGoogle Scholar
• Deyoung CG, Cicchetti D, Rogosch FA. 2011. Moderation of the association between childhood maltreatment and neuroticism by the corticotropin-releasing hormone receptor 1 gene. J Child Psychol Psychiatry 52(8):898–906.
   PubMedGoogle Scholar
• Drago A, De Ronchi D, Serretti A. 2009. Pharmacogenetics of antidepressant response: an update. Hum Genomics 3(3): 257–274.
   PubMedGoogle Scholar
• Dudley KJ, Li X, Kobor MS, Kippin TE, Bredy TW. 2011. Epigenetic mechanisms mediating vulnerability and resilience to psychiatric disorders. Neurosci Biobehav Rev [Epub ahead of print].
   PubMedGoogle Scholar
• Elder BL, Mosack V. 2011. Genetics of depression: an overview of the current science. Issues Ment Health Nurs 32(4): 192–202.
   PubMedGoogle Scholar
• Feder A, Nestler EJ, Charney DS. 2009. Psychobiology and molecular genetics of resilience. Nat Rev Neurosci 10(6): 446–457.
   PubMedGoogle Scholar
• Fekete EM, Zorrilla EP. 2007. Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs. Front Neuroendocrinol 28(1):1–27.
   PubMedGoogle Scholar
• Fish EW, Shahrokh D, Bagot R, Caldji C, Bredy T, Szyf M, Meaney MJ. 2004. Epigenetic programming of stress responses through variations in maternal care. Ann NY Acad Sci 1036: 167–180.
   PubMed Web of Science ®Google Scholar
• Gallagher JP, Orozco-Cabal LF, Liu J, Shinnick-Gallagher P. 2008. Synaptic physiology of central CRH system. Eur J Pharmacol 583(2–3):215–225.
   PubMedGoogle Scholar
• Gex-Fabry M, Eap CB, Oneda B, Gervasoni N, Aubry JM, Bondolfi G, Bertschy G. 2008. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Ther Drug Monit 30(4):474–482.
   PubMed Web of Science ®Google Scholar
• Glessner JT, Wang K, Sleiman PM, Zhang H, Kim CE, Flory JH, . 2010. Duplication of the SLIT3 locus on 5q35.1 predisposes to major depressive disorder. PLoS One 5(12):e15463.
   PubMedGoogle Scholar
• Grabe HJ, Schwahn C, Appel K, Mahler J, Schulz A, Spitzer C, . 2010. Childhood maltreatment, the corticotropin-releasing hormone receptor gene and adult depression in the general population. Am J Med Genet B Neuropsychiatr Genet 153B(8):1483–1493.
   PubMedGoogle Scholar
• Griebel G, Perrault G, Sanger DJ. 1998. Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents. Comparison with diazepam and buspirone. Psychopharmacology (Berlin) 138(1):55–66.
   PubMedGoogle Scholar
• Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, . 2002. Anxiolytic- and antidepressant- like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci USA 99(9):6370–6375.
   PubMedGoogle Scholar
• Grigoriadis DE. 2005. The corticotropin-releasing factor receptor: a novel target for the treatment of depression and anxiety-related disorders. Expert Opin Ther Targets 9(4):651–684.
   PubMedGoogle Scholar
• Groves JO. 2007. Is it time to reassess the BDNF hypothesis of depression? Mol Psychiatry 12(12):1079–1088.
   PubMed Web of Science ®Google Scholar
• Gysling K, Forray MI, Haeger P, Daza C, Rojas R. 2004. Corticotropin-releasing hormone and urocortin: redundant or distinctive functions? Brain Res Brain Res Rev 47(1–3): 116–125.
   PubMedGoogle Scholar
• Habib KE, Weld KP, Rice KC, Pushkas J, Champoux M, Listwak S, . 2000. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc Natl Acad Sci USA 97(11):6079–6084.
   PubMed Web of Science ®Google Scholar
• Hauger RL, Grigoriadis DE, Dallman MF, Plotsky PM, Vale WW, Dautzenberg FM. 2003. International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands. Pharmacol Rev 55(1):21–26.
   PubMedGoogle Scholar
• Heinrichs SC, De Souza EB, Schulteis G, Lapsansky JL, Grigoriadis DE. 2002. Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist. Neuro psychopharmacology 27(2):194–202.
   Google Scholar
• Heinrichs M, Baumgartner T, Kirschbaum C, Ehlert U. 2003. Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. Biol Psychiatry 54(12):1389–1398.
   PubMedGoogle Scholar
• Hennings JM, Owashi T, Binder EB, Horstmann S, Menke A, Kloiber S, . 2009. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients – findings from the Munich Antidepressant Response Signature (MARS) project. J Psychiatr Res 43(3):215–229.
   PubMedGoogle Scholar
• Heuser I, Yassouridis A, Holsboer F. 1994. The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J Psychiatr Res 28(4):341–356.
   PubMedGoogle Scholar
• Holsboer F. 2008. How can we realize the promise of personalized antidepressant medicines? Nat Rev Neurosci 9(8):638–646.
   PubMedGoogle Scholar
• Holsboer F, Ising M. 2008. Central CRH system in depression and anxiety – evidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol 583(2–3):350–357.
   PubMed Web of Science ®Google Scholar
• Holsboer F, Ising M. 2010. Stress hormone regulation: biological role and translation into therapy. Annu Rev Psychol 61:81–109, C1–11.
   PubMed Web of Science ®Google Scholar
• Holsboer F, von Bardeleben U, Buller R, Heuser I, Steiger A. 1987. Stimulation response to corticotropin-releasing hormone (CRH) in patients with depression, alcoholism and panic disorder. Horm Metab Res Suppl 16:80–88.
   PubMedGoogle Scholar
• Horstmann S, Lucae S, Menke A, Hennings JM, Ising M, Roeske D, . 2010. Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology 35(3): 727–740.
   PubMedGoogle Scholar
• Illi A, Setala-Soikkeli E, Viikki M, Poutanen O, Huhtala H, Mononen N, . 2009. 5–HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. Neuroreport 20(12):1125–1128.
   PubMedGoogle Scholar
• Ising M, Kunzel HE, Binder EB, Nickel T, Modell S, Holsboer F. 2005. The combined dexamethasone/CRH test as a potential surrogate marker in depression. Prog Neuropsychopharmacol Biol Psychiatry 29(6):1085–1093.
   PubMedGoogle Scholar
• Ising M, Horstmann S, Kloiber S, Lucae S, Binder EB, Kern N, . 2007. Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression – a potential biomarker? Biol Psychiatry 62(1): 47–54.
   PubMedGoogle Scholar
• Ising M, Lucae S, Binder EB, Bettecken T, Uhr M, Ripke S, . 2009. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry 66(9):966–975.
   PubMed Web of Science ®Google Scholar
• Juhasz G, Dunham JS, McKie S, Thomas E, Downey D, Chase D, . 2011. The CREB1-BDNF-NTRK2 pathway in depression: multiple gene-cognition-environment interactions. Biol Psychiatry 69(8):762–771.
   PubMedGoogle Scholar
• Kanellopoulos D, Gunning FM, Morimoto SS, Hoptman MJ, Murphy CF, Kelly RE, . 2011. Hippocampal volumes and the brain-derived neurotrophic factor val66met polymorphism in geriatric major depression. Am J Geriatr Psychiatry 19(1):13–22.
   PubMedGoogle Scholar
• Karg K, Burmeister M, Shedden K, Sen S. 2011. The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation. Arch Gen Psychiatry 68(5):444–54.
   PubMedGoogle Scholar
• Kaufman J, Yang BZ, Douglas-Palumberi H, Houshyar S, Lipschitz D, Krystal JH, Gelernter J. 2004. Social supports and serotonin transporter gene moderate depression in maltreated children. Proc Natl Acad Sci USA 101(49): 17316–17321.
   PubMedGoogle Scholar
• Kaufman J, Yang BZ, Douglas-Palumberi H, Grasso D, Lipschitz D, Houshyar S, . 2006. Brain-derived neurotrophic factor-5-HTTLPR gene interactions and environmental modifiers of depression in children. Biol Psychiatry 59(8): 673–680.
   PubMed Web of Science ®Google Scholar
• Kaymak SU, Demir B, Senturk S, Tatar I, Aldur MM, Ulug B. 2010. Hippocampus, glucocorticoids and neurocognitive functions in patients with first-episode major depressive disorders. Eur Arch Psychiatry Clin Neurosci 260(3):217–223.
   PubMedGoogle Scholar
• Keck ME, Welt T, Müller MB, Landgraf R, Holsboer F. 2003a. The high-affinity non-peptide CRH1 receptor antagonist R121919 attenuates stress-induced alterations in plasma oxytocin, prolactin, and testosterone secretion in rats. Pharmacopsychiatry 36(1):27–31.
   PubMedGoogle Scholar
• Keck ME, Welt T, Muller MB, Uhr M, Ohl F, Wigger A, . 2003b. Reduction of hypothalamic vasopressinergic hyperdrive contributes to clinically relevant behavioral and neuroendocrine effects of chronic paroxetine treatment in a psychopathological rat model. Neuropsychopharmacology 28(2):235–243.
   PubMedGoogle Scholar
• Keers R, Uher R, Huezo-Diaz P, Smith R, Jaffee S, Rietschel M, . 2011. Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project. Pharmacogenomics J 11(2): 138–145.
   PubMedGoogle Scholar
• Kimchi-Sarfaty C, Marple AH, Shinar S, Kimchi AM, Scavo D, Roma MI, . 2007. Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene. Pharmacogenomics 8(1):29–39.
   PubMedGoogle Scholar
• Kirchheiner J, Lorch R, Lebedeva E, Seeringer A, Roots I, Sasse J, Brockmoller J. 2008. Genetic variants in FKBP5 affecting response to antidepressant drug treatment. Pharmacogenomics 9(7):841–846.
   PubMedGoogle Scholar
• Kohli MA, Lucae S, Saemann PG, Schmidt MV, Demirkan A, Hek K, . 2011. The neuronal transporter gene SLC6A15 confers risk to major depression. Neuron 70(2):252–265.
   PubMedGoogle Scholar
• Künzel HE, Zobel AW, Nickel T, Ackl N, Uhr M, Sonntag A, . 2003. Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects. J Psychiatr Res 37(6):525–533.
   PubMedGoogle Scholar
• Kupfer DJ. 2005. Achieving adequate outcomes in geriatric depression: standardized criteria for remission. J Clin Psychopharmacol 25(4 Suppl 1):S24–28.
   PubMedGoogle Scholar
• Lancel M, Muller-Preuss P, Wigger A, Landgraf R, Holsboer F. 2002. The CRH1 receptor antagonist R121919 attenuates stress-elicited sleep disturbances in rats, particularly in those with high innate anxiety. J Psychiatr Res 36(4):197–208.
   PubMedGoogle Scholar
• Landgraf R. 2006. Neuropeptides in anxiety and depression. Amino Acids 31(3):211–213.
   PubMedGoogle Scholar
• Lavebratt C, Aberg E, Sjoholm LK, Forsell Y. 2010. Variations in FKBP5 and BDNF genes are suggestively associated with depression in a Swedish population-based cohort. J Affect Disord 125(1–3):249–255.
   PubMedGoogle Scholar
• Lekman M, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ, . 2008. The FKBP5-gene in depression and treatment response – an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Biol Psychiatry 63(12):1103–1110.
   PubMedGoogle Scholar
• Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, . 1996. Association of anxiety-related traits with a poly morphism in the serotonin transporter gene regulatory region. Science 274(5292):1527–1531.
   PubMed Web of Science ®Google Scholar
• Lewis G, Mulligan J, Wiles N, Cowen P, Craddock N, Ikeda M, . 2011. Polymorphism of the 5-HT transporter and response to antidepressants: randomised controlled trial. Br J Psychiatry 198(6):464–71.
   PubMedGoogle Scholar
• Licinio J, O'Kirwa F, Irizarry K, Merriman B, Thakur S, Jepson R, . 2004. Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans. Mol Psychiatry 9(12): 1075–1082.
   PubMedGoogle Scholar
• Liebsch G, Landgraf R, Engelmann M, Lorscher P, Holsboer F. 1999. Differential behavioural effects of chronic infusion of CRH 1 and CRH 2 receptor antisense oligonucleotides into the rat brain. J Psychiatr Res 33(2):153–163.
   PubMedGoogle Scholar
• Lin KM, Chiu YF, Tsai IJ, Chen CH, Shen WW, Liu SC, . 2011. ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment. Pharmacogenet Genomics 21(4):163–170.
   PubMedGoogle Scholar
• Liu Z, Zhu F, Wang G, Xiao Z, Tang J, Liu W, . 2007. Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders. Neurosci Lett 414(2):155–158.
   PubMedGoogle Scholar
• Lucae S, Ising M, Horstmann S, Baune BT, Arolt V, Muller-Myhsok B, . 2010. HTR2A gene variation is involved in antidepressant treatment response. Eur Neuropsychopharmacol 20(1):65–68.
   PubMedGoogle Scholar
• Ma XM, Lightman SL. 1998. The arginine vasopressin and corticotrophin-releasing hormone gene transcription responses to varied frequencies of repeated stress in rats. J Physiol 510 (Pt 2):605–614.
   PubMed Web of Science ®Google Scholar
• Ma XM, Levy A, Lightman SL. 1997. Emergence of an isolated arginine vasopressin (AVP) response to stress after repeated restraint: a study of both AVP and corticotropin-releasing hormone messenger ribonucleic acid (RNA) and heteronuclear RNA. Endocrinology 138(10):4351–4357.
   PubMedGoogle Scholar
• Malykhin NV, Carter R, Seres P, Coupland NJ. 2010. Structural changes in the hippocampus in major depressive disorder: contributions of disease and treatment. J Psychiatry Neurosci 35(5):337–343.
   PubMedGoogle Scholar
• Mason BL, Pariante CM. 2006. The effects of antidepressants on the hypothalamic-pituitary-adrenal axis. Drug News Perspect 19(10):603–608.
   PubMedGoogle Scholar
• McGowan PO, Sasaki A, D'Alessio AC, Dymov S, Labonte B, Szyf M, . 2009. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci 12(3):342–348.
   PubMed Web of Science ®Google Scholar
• McGowan PO, Suderman M, Sasaki A, Huang TC, Hallett M, Meaney MJ, Szyf M. 2011. Broad epigenetic signature of maternal care in the brain of adult rats. PLoS One 6(2): e14739.
   PubMed Web of Science ®Google Scholar
• Menu P, Gressier F, Verstuyft C, Hardy P, Becquemont L, Corruble E. 2010. Antidepressants and ABCB1 gene C3435T functional polymorphism: a naturalistic study. Neuropsychobiology 62(3):193–197.
   PubMedGoogle Scholar
• Meyer-Lindenberg A. 2008. Impact of prosocial neuropeptides on human brain function. Prog Brain Res 170:463–470.
   PubMed Web of Science ®Google Scholar
• Meyer-Lindenberg A, Domes G, Kirsch P, Heinrichs M. 2011. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat Rev Neurosci 12(9): 524–538.
   PubMedGoogle Scholar
• Mill J, Petronis A. 2007. Molecular studies of major depressive disorder: the epigenetic perspective. Mol Psychiatry 12(9): 799–814.
   PubMedGoogle Scholar
• Muglia P, Tozzi F, Galwey NW, Francks C, Upmanyu R, Kong XQ, . 2010. Genome-wide association study of recurrent major depressive disorder in two European case-control cohorts. Mol Psychiatry 15(6):589–601.
   PubMed Web of Science ®Google Scholar
• Müller-Myhsok B. 2005. The usefulness of single nucleotide polymorphisms (SNPs) for genetic epidemiological investigation of complex psychiatric diseases. Prog Neuropsychopharmacol Biol Psychiatry 29(6):1017–1020.
   PubMedGoogle Scholar
• Munafo MR, Durrant C, Lewis G, Flint J. 2009a. Gene × environment interactions at the serotonin transporter locus. Biol Psychiatry 65(3):211–219.
   PubMedGoogle Scholar
• Munafo MR, Freimer NB, Ng W, Ophoff R, Veijola J, Miettunen J, . 2009b. 5-HTTLPR genotype and anxiety-related personality traits: a meta-analysis and new data. Am J Med Genet B Neuropsychiatr Genet 150B(2):271–281.
   PubMed Web of Science ®Google Scholar
• Neufeld-Cohen A, Tsoory MM, Evans AK, Getselter D, Gil S, Lowry CA, . 2010. A triple urocortin knockout mouse model reveals an essential role for urocortins in stress recovery. Proc Natl Acad Sci USA 107(44):19020–19025.
   PubMedGoogle Scholar
• Nierenberg AA, Leon AC, Price LH, Shelton RC, Trivedi MH. 2011. The current crisis of confidence in antidepressants. J Clin Psychiatry 72(1):27–33.
   PubMedGoogle Scholar
• Nifosi F, Toffanin T, Follador H, Zonta F, Padovan G, Pigato G, . 2010. Reduced right posterior hippocampal volume in women with recurrent familial pure depressive disorder. Psychiatry Res 184(1):23–28.
   PubMedGoogle Scholar
• Nikisch G, Eap CB, Baumann P. 2008. Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. Pharmacol Res 58(5–6):344–347.
   PubMedGoogle Scholar
• Papiol S, Arias B, Gasto C, Gutierrez B, Catalan R, Fananas L. 2007. Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. J Affect Disord 104(1–3):83–90.
   PubMedGoogle Scholar
• Perlis RH, Fijal B, Dharia S, Heinloth AN, Houston JP. 2010. Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients. Biol Psychiatry 67(11):1110–1113.
   PubMedGoogle Scholar
• Perroud N, Bondolfi G, Uher R, Gex-Fabry M, Aubry JM, Bertschy G, . 2011. Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. Pharmacogenomics 12(3):365–377.
   PubMedGoogle Scholar
• Ressler KJ, Bradley B, Mercer KB, Deveau TC, Smith AK, Gillespie CF, . 2010. Polymorphisms in CRHR1 and the serotonin transporter loci: gene x gene x environment interactions on depressive symptoms. Am J Med Genet B Neuropsychiatr Genet 153B(3):812–824.
   PubMedGoogle Scholar
• Rudan I. 2010. New technologies provide insights into genetic basis of psychiatric disorders and explain their co-morbidity. Psychiatr Danub 22(2):190–192.
   PubMedGoogle Scholar
• Rupprecht R, Holsboer F. 1999. Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci 22(9):410–416.
   PubMedGoogle Scholar
• Rupprecht R, Rammes G, Eser D, Baghai TC, Schule C, Nothdurfter C, . 2009. Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science 325(5939):490–493.
   PubMedGoogle Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, . 2006. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163(11):1905–1917.
   PubMed Web of Science ®Google Scholar
• Sarginson JE, Lazzeroni LC, Ryan HS, Schatzberg AF, Murphy GM Jr. 2010. FKBP5 polymorphisms and antidepressant response in geriatric depression. Am J Med Genet B Neuropsychiatr Genet 153B(2):554–560.
   PubMedGoogle Scholar
• Sato H, Horikawa Y, Iizuka K, Sakurai N, Tanaka T, Shihara N, . 2008. Large-scale analysis of glucocorticoid target genes in rat hypothalamus. J Neurochem 106(2):805–814.
   PubMedGoogle Scholar
• Scantamburlo G, Hansenne M, Fuchs S, Pitchot W, Marechal P, Pequeux C, . 2007. Plasma oxytocin levels and anxiety in patients with major depression. Psychoneuroendocrinology 32(4):407–410.
   PubMedGoogle Scholar
• Schinka JA, Busch RM, Robichaux-Keene N. 2004. A meta- analysis of the association between the serotonin transporter gene polymorphism (5-HTTLPR) and trait anxiety. Mol Psychiatry 9(2):197–202.
   PubMedGoogle Scholar
• Schroeder M, Krebs MO, Bleich S, Frieling H. 2010. Epigenetics and depression: current challenges and new therapeutic options. Curr Opin Psychiatry 23(6):588–592.
   PubMedGoogle Scholar
• Schüle C. 2007. Neuroendocrinological mechanisms of actions of antidepressant drugs. J Neuroendocrinol 19(3):213–226.
   PubMedGoogle Scholar
• Schüle C, Zill P, Baghai TC, Eser D, Zwanzger P, Wenig N, . 2006. Brain-derived neurotrophic factor Val66Met polymorphism and dexamethasone/CRH test results in depressed patients. Psychoneuroendocrinology 31(8):1019–1025.
   PubMedGoogle Scholar
• Schüle C, Baghai TC, Eser D, Rupprecht R. 2009. Hypothalamic-pituitary-adrenocortical system dysregulation and new treatment strategies in depression. Expert Rev Neurother 9(7): 1005–1019.
   PubMedGoogle Scholar
• Serradeil-Le Gal C, Wagnon J, Simiand J, Griebel G, Lacour C, Guillon G, . 2002. Characterization of (2S,4R)-1- [5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N, N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. J Pharmacol Exp Ther 300(3):1122–1130.
   PubMedGoogle Scholar
• Serretti A, Olgiati P, Bajo E, Bigelli M, De Ronchi D. 2011. A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders. World J Biol Psychiatry 12(7):501–15.
   PubMedGoogle Scholar
• Shyn SI, Shi J, Kraft JB, Potash JB, Knowles JA, Weissman MM, . 2011. Novel loci for major depression identified by genome-wide association study of sequenced treatment alternatives to relieve depression and meta-analysis of three studies. Mol Psychiatry 16(2):202–215.
   PubMedGoogle Scholar
• Skelton KH, Nemeroff CB, Knight DL, Owens MJ. 2000. Chronic administration of the triazolobenzodiazepine alprazolam produces opposite effects on corticotropin-releasing factor and urocortin neuronal systems. J Neurosci 20(3):1240–1248.
   PubMedGoogle Scholar
• Soravia LM, Heinrichs M, Aerni A, Maroni C, Schelling G, Ehlert U, . 2006. Glucocorticoids reduce phobic fear in humans. Proc Natl Acad Sci USA 103(14):5585–5590.
   PubMedGoogle Scholar
• Stein DJ. 2009. Oxytocin and vasopressin: social neuropeptides. CNS Spectr 14(11):602–606.
   PubMedGoogle Scholar
• Strohmaier J, Wust S, Uher R, Henigsberg N, Mors O, Hauser J, . 2011. Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: Clinical description and the role of the 5-HTTLPR. World J Biol Psychiatry 2(7): 528–38.
   Google Scholar
• Suchanek R, Owczarek A, Kowalczyk M, Kucia K, Kowalski J. 2011. Association between C-281A and val66met functional polymorphisms of BDNF gene and risk of recurrent major depressive disorder in Polish population. J Mol Neurosci 43(3):524–530.
   PubMedGoogle Scholar
• Sullivan PF, de Geus EJ, Willemsen G, James MR, Smit JH, Zandbelt T, . 2009. Genome-wide association for major depressive disorder: a possible role for the presynaptic protein piccolo. Mol Psychiatry 14(4):359–375.
   PubMedGoogle Scholar
• Sun RF, Zhu YS, Kuang WJ, Liu Y, Li SB. 2011. The G-712A polymorphism of brain-derived neurotrophic factor is associated with major depression but not schizophrenia. Neurosci Lett 489(1):34–37.
   PubMedGoogle Scholar
• Tanaka M, Telegdy G. 2008. Antidepressant-like effects of the CRF family peptides, urocortin 1, urocortin 2 and urocortin 3 in a modified forced swimming test in mice. Brain Res Bull 75(5):509–512.
   PubMedGoogle Scholar
• Taylor MJ, Sen S, Bhagwagar Z. 2010. Antidepressant response and the serotonin transporter gene-linked polymorphic region. Biol Psychiatry 68(6):536–543.
   PubMed Web of Science ®Google Scholar
• Terracciano A, Tanaka T, Sutin AR, Sanna S, Deiana B, Lai S, . 2011. Genome-wide association scan of trait depression. Biol Psychiatry 68(9):811–817.
   Google Scholar
• Tsai SJ, Hong CJ, Chen TJ, Yu YW. 2007. Lack of supporting evidence for a genetic association of the FKBP5 polymorphism and response to antidepressant treatment. Am J Med Genet B Neuropsychiatr Genet 144B(8):1097–1098.
   PubMedGoogle Scholar
• Tsatsanis C, Dermitzaki E, Venihaki M, Chatzaki E, Minas V, Gravanis A, Margioris AN. 2007. The corticotropin-releasing factor (CRF) family of peptides as local modulators of adrenal function. Cell Mol Life Sci 64(13):1638–1655.
   PubMedGoogle Scholar
• Uher R, Caspi A, Houts R, Sugden K, Williams B, Poulton R, Moffitt TE. 2011. Serotonin transporter gene moderates childhood maltreatment's effects on persistent but not single- episode depression: Replications and implications for resolving inconsistent results. J Affect Disord [Epub ahead of print].
   Google Scholar
• Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, . 2008. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 57(2):203–209.
   PubMedGoogle Scholar
• van Rossum EF, Binder EB, Majer M, Koper JW, Ising M, Modell S, . 2006. Polymorphisms of the glucocorticoid receptor gene and major depression. Biol Psychiatry 59(8): 681–688.
   PubMedGoogle Scholar
• van West D, Del-Favero J, Aulchenko Y, Oswald P, Souery D, Forsgren T, . 2004. A major SNP haplotype of the arginine vasopressin 1B receptor protects against recurrent major depression. Mol Psychiatry 9(3):287–292.
   PubMedGoogle Scholar
• Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S, . 1995. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 378(6554):287–292.
   PubMedGoogle Scholar
• Velders FP, Kuningas M, Kumari M, Dekker MJ, Uitterlinden AG, Kirschbaum C, . 2011. Genetics of cortisol secretion and depressive symptoms: A candidate gene and genome wide association approach. Psychoneuroendocrinology [Epub ahead of print].
   PubMedGoogle Scholar
• von Bardeleben U, Holsboer F. 1988. Human corticotropin releasing hormone: clinical studies in patients with affective disorders, alcoholism, panic disorder and in normal controls. Prog Neuropsychopharmacol Biol Psychiatry 12(Suppl): S165–187.
   PubMedGoogle Scholar
• von Bardeleben U, Holsboer F, Stalla GK, Muller OA. 1985. Combined administration of human corticotropin-releasing factor and lysine vasopressin induces cortisol escape from dexamethasone suppression in healthy subjects. Life Sci 37(17):1613–1618.
   PubMedGoogle Scholar
• Wankerl M, Wust S, Otte C. 2010. Current developments and controversies: does the serotonin transporter gene-linked polymorphic region (5-HTTLPR) modulate the association between stress and depression? Curr Opin Psychiatry 23(6): 582–587.
   PubMedGoogle Scholar
• Wasserman D, Sokolowski M, Rozanov V, Wasserman J. 2008. The CRHR1 gene: a marker for suicidality in depressed males exposed to low stress. Genes Brain Behav 7(1):14–19.
   PubMedGoogle Scholar
• Weaver IC, Cervoni N, Champagne FA, D'Alessio AC, Sharma S, Seckl JR, . 2004. Epigenetic programming by maternal behavior. Nat Neurosci 7(8):847–854.
   PubMedGoogle Scholar
• Weaver IC, Champagne FA, Brown SE, Dymov S, Sharma S, Meaney MJ, Szyf M. 2005. Reversal of maternal programming of stress responses in adult offspring through methyl supplementation: altering epigenetic marking later in life. J Neurosci 25(47):11045–11054.
   PubMedGoogle Scholar
• Weaver IC, Meaney MJ, Szyf M. 2006. Maternal care effects on the hippocampal transcriptome and anxiety-mediated behaviors in the offspring that are reversible in adulthood. Proc Natl Acad Sci USA 103(9):3480–3485.
   PubMedGoogle Scholar
• Williams LM, Rush AJ, Koslow SH, Wisniewski SR, Cooper NJ, Nemeroff CB, . 2011. International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol. Trials 12:4.
   PubMedGoogle Scholar
• Willis-Owen SA, Turri MG, Munafo MR, Surtees PG, Wainwright NW, Brixey RD, Flint J. 2005. The serotonin transporter length polymorphism, neuroticism, and depression: a comprehensive assessment of association. Biol Psychiatry 58(6):451–456.
   PubMed Web of Science ®Google Scholar
• Zak PJ, Stanton AA, Ahmadi S. 2007. Oxytocin increases gene rosity in humans. PLoS One 2(11):e1128.
   PubMedGoogle Scholar
• Zimmermann U, Spring K, Kunz-Ebrecht SR, Uhr M, Wittchen HU, Holsboer F. 2004. Effect of ethanol on hypothalamic- pituitary-adrenal system response to psychosocial stress in sons of alcohol-dependent fathers. Neuropsychopharmacology 29(6):1156–1165.
   PubMedGoogle Scholar
• Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M, Holsboer F. 2000. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 34(3): 171–181.
   PubMedGoogle Scholar
• Zou YF, Wang F, Feng XL, Li WF, Tao JH, Pan FM, . 2010. Meta-analysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders. Neurosci Lett 484(1):56–61.
   PubMedGoogle Scholar